Reducing impairment while maintaining pain management benefits is one possibility flowing from the work of Alberta researchers who have identified what they call a metabolic fingerprint related to medical cannabis use.
To gain insight, investigators explored “a novel panel of blood-based metabolites that are predictive, diagnostic and/or prognostic of behavioural effects.”
In a study of male rats, the animals were administered a medical-grade, full-spectrum cannabis extract with THC, CBD and other compounds, cannabis extract with CBD and all other weed compounds or an unidentified vehicle oil.
After four hours, investigators assessed the rats’ behaviour by having them run a maze. Blood was collected and metabolites — substances produced when the body breaks down food, drugs or tissues like fat or muscle — were identified and quantified.
“We found that only rats treated with full-spectrum cannabis extract exhibited behavioural changes,” authors note in the study.
Read full article on The Growth Op
